Zhejiang Jingxin Pharmaceutical Co., Ltd.

Up to now, the company has a registered capital of 725 million yuan, total assets of 5 billion yuan and net assets of 3.9 billion yuan. The company has more than 2,700 employees, including 34 doctors and more than 150 masters.The company has two headquarters in Xinchang and Hangzhou. It has six production sites including the plant in Xinchang for finished medicines, the two API plants in Shangyu and Shangrao, the TCM production site in Bayannaoer, Inner Mongolia, and the medical equipment production base of Shenzhen and Shenyang. Aside from that, the company also owns a breeding base in Yunnan. In Shanghai, the company has established its own research institute i n the Zhangjiang Hi-Tech Park. Joint ventures and collaberated labs have also been founded over the years in the U.S.A., the U.K., Denmark, Isereal, Korea as well as other countries.All along, the company has been adhering to the "Jingxin drug, meticulously made" quality concept. It has passed the new version of GMP certification, the solid preparation production line took the lead in 2006 by passing the German GMP certification. In 2018, it also passed the FDA on-site certification. The company's comprehensive economics have been rapidly improved. It was listed as one of the "Top 100 Chinese Pharmaceutical Industry Brands", "Top 100 Chinese Pharmaceutical Industry" and "Top 100 Chinese Chemical Pharmaceutical Enterprises" for many years. It was recognized as the first batch of " Leading Chinese pharmaceutical companies in the internationalization of preparations", gainging increasing the social popularity and reputation.